Skip to content
Screener

Dyne Therapeutics, Inc. DYN Total Liabilities

Total Liabilities at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.66B-28.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.55B+8.6%
Wave Life Sciences logo
Wave Life SciencesWVE
$104.8M-0.4%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$46.51M-7.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$25.32M+2.6%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$12.39M+29.6%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemMarch 31, 2026December 31, 2025
Total current liabilities51,24950,625
Long-term debt, net149,375148,921
Lease liabilities, net of current portion14,27115,283
Total liabilities214,895214,829
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 165,201,329 and 164,950,540 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1616
Additional paid-in capital2,382,1722,367,780

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s total liabilities?
Dyne Therapeutics, Inc. (DYN) reported total liabilities of $214.9M in Q1 2026.
How has Dyne Therapeutics, Inc.'s total liabilities changed year-over-year?
Dyne Therapeutics, Inc.'s total liabilities increased by 312.5% year-over-year, from $52.1M to $214.9M.
What is the long-term trend for Dyne Therapeutics, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s total liabilities has grown at a 81.3% compound annual growth rate (CAGR), from $10.97M to $214.83M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Dyne Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude